Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma

Glioblastoma (GBM) is one of the most aggressive central nervous system tumors with a patient’s median survival of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer gene therapy 2013-09, Vol.20 (9), p.499-506
Hauptverfasser:	Pezuk, J A, Brassesco, M S, Morales, A G, de Oliveira, J C, de Paula Queiroz, R G, Machado, H R, Carlotti, C G, Neder, L, Scrideli, C A, Tone, L G
Format:	Artikel
Sprache:	eng
Schlagworte:	631/80/641 631/80/82 692/699/67/1922 Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - pharmacology Apoptosis Biomedical and Life Sciences Biomedicine Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - metabolism Care and treatment Causes of Cell cycle Cell Cycle Checkpoints - drug effects Cell Cycle Checkpoints - genetics Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - genetics Cell death Cell Death - drug effects Cell Death - genetics Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Central nervous system Dacarbazine - administration & dosage Dacarbazine - analogs & derivatives Dacarbazine - pharmacology DNA damage Drug Synergism Gene Expression Gene Therapy Glioblastoma Glioblastoma - drug therapy Glioblastoma - genetics Glioblastoma - metabolism Glioblastoma multiforme Humans Kinases original-article Patient outcomes Phosphotransferases Physiological aspects Polo-like kinase Polo-Like Kinase 1 Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacology Protein Serine-Threonine Kinases - antagonists & inhibitors Protein Serine-Threonine Kinases - genetics Proto-Oncogene Proteins - antagonists & inhibitors Proto-Oncogene Proteins - genetics Temozolomide Threonine Tumor cell lines Tumor Stem Cell Assay Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!